Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820829 | 0.88 | ESR1 (0.57) | ESR1ESR2HSD17B1PPARAPPARG | |
| SCHEMBL13925659 | 0.83 | ESR1 (0.56) | ESR1ESR2HSD17B1PPARAPPARG | |
| SCHEMBL821080 | 0.78 | ESR1 (0.57) | ESR1ESR2PPARAPPARGECE1 | |
| SCHEMBL1400682 | 0.78 | ESR1 (0.57) | ESR1ESR2PPARAPPARGECE1 | |
| SCHEMBL820847 | 0.76 | ESR1 (0.61) | ESR1ESR2PPARAPPARG | |
| SCHEMBL5789865 | 0.76 | ESR1 (0.61) | ESR1ESR2PPARAPPARG | |
| SCHEMBL6310197 | 0.76 | ESR1 (0.61) | ESR1ESR2PPARAPPARG | |
| SCHEMBL1400719 | 0.76 | ESR1 (0.61) | ESR1ESR2PPARAPPARG | |
| SCHEMBL820547 | 0.76 | ESR1 (0.61) | ESR1ESR2PPARAPPARG | |
| SCHEMBL20222854 | 0.76 | ESR1 (0.61) | ESR1ESR2PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-03-17 | — | — | US | disclosed |
| WO-2010141696-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | ESR1 3666/4885ESR2 3935/4885HSD17B1 149/4885 |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | ESR1 3666/4885ESR2 3935/4885HSD17B1 149/4885 |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | ESR1 3666/4885ESR2 3935/4885HSD17B1 149/4885 |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | INSR, ACACA, IAPP | ESR1 3666/4885ESR2 3935/4885HSD17B1 149/4885 |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | APP, MAPT, TNF | ESR1 2205/4885ESR2 2366/4885HSD17B1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.